Correlogic Developing 'Second Generation' OvaCheck; Seeks Ruling on Quest, LabCorp Licenses

The development of this second-generation test, which in court documents the company has referred to as OvaCheck 2, has potentially important implications for Correlogic in its ongoing licensing dispute and for the firm's eventual sale of its assets.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.